Coenzyme-A Inc.
Coenzyme-A Inc.
Your view on PPII
Overview
What the company does, where it operates, and who runs it.
About Coenzyme-A Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Nickoloaus D. Skouras
- Headquarters
- 12512 Beverly Park Road, Lynnwood, WA, US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Nickoloaus D. Skouras
- Headquarters
- 12512 Beverly Park Road, Lynnwood, WA, US
Coenzyme-A Inc. formulates and manufactures nutraceutical supplements, and skin and hair care products in the United States and internationally.
It offers energy drinks and skin rejuvinating serums, as well as fat management, skin treatment, fatty acid and cholesterol metabolism, and skin rejuvenating products, as well as nutritional formulas for the support of bone, joint, ligament, cartilage, and connective tissue functions.
The company also provides sports-specific, women's, and men's formulas, as well as wellness, energy, and body sculpting products. Coenzyme-A Inc. was founded in 1998 and is based in Lynnwood, Washington.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Coenzyme-A Inc., and the rating behind it. PPII last traded at $0.0002; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Coenzyme-A Inc.. Starting points for Coenzyme-A Inc.: EPS -$35.31, beta 1.58 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Coenzyme-A Inc.. Coenzyme-A Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Coenzyme-A Inc.. Trailing twelve-month EPS for Coenzyme-A Inc. stands at -$35.31. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Coenzyme-A Inc.. Coenzyme-A Inc. has reported as a listed company since 2009. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Coenzyme-A Inc. valued side by side against its closest peers. Coenzyme-A Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Coenzyme-A Inc., and how their positions are changing. At a $111 market value, institutional positions materially move Coenzyme-A Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Coenzyme-A Inc. executives and directors. Shares of Coenzyme-A Inc. have traded between $0.0002 and $0.0002 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Coenzyme-A Inc.. Coenzyme-A Inc. is a $111 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Coenzyme-A Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Coenzyme-A Inc.. Coverage tracks Coenzyme-A Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.